Peptide Therapy

Semaglutide, sold under the brand names Ozempic (FDA Approved 2017), Wegovy (FDA Approved 2021), & Rybelsus (FDA Approved 2019).

Losing weight can be an incredibly difficult endeavor which can impact your lifestyle. We all know there are no magic pills & nothing works better than time & effort. Bergen Total Health offers medications that are available that can assist with weight loss, fat loss, & even helps control insulin levels. The best part, these medications only have to be administered once a week.

Semaglutide, often referred to by the brand names Ozempic and Wegovy®, is a Glucagon-like peptide-1 (GLP-1) produced by the gut. It increases insulin production, a hormone that lowers the blood sugar level while inhibiting glucagon secretion, which is a hormone that raises blood sugar, reduces appetite and energy intake while delaying gastric emptying. It was first developed in 2012 by Novo Nordisk as a longer-acting option to Liraglutide. In 2017 this drug was approved as an anti-diabetic medication used to treat type 2 diabetes and obesity. In June 2021, it got approved for chronic weight management in obese individuals with a (BMI) ≥ 30 kg/m2) or overweight (initial BMI ≥ 27 kg/m2) with at least one weight-related comorbidity.

Benefits of Semaglutide Peptide Therapy over time:

• Reduces food intake by lowering appetite
• Slows food digestion in the stomach
• Decrease in overall body weight
• Decreased cardiovascular outcomes in subjects with type 2 diabetes
• Lower HbA1c levels
• Enhance the growth of β cells in the pancreas

Risks:

The most common side effects may include: nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, gas, & heartburn.